Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CAR Targets for Hematological Malignancies

CAR Targets for Hematological Malignancies

CAR Targets for Hematological Malignancies
Background
Chimeric antigen receptor T (CAR-T) cell therapies, following its regulatory approval, has been frequently considered a breakthrough therapy regarding hematological tumors. Currently, only CD19 and BCMA have been approved as targets against refractory large B-cell lymphoma. However, research has highlighted more than 30 other targets that has shown potential in combating other hematological malignancies.
CAR Targets for Hematological Malginancies
B cell Leukemia/
Lymphoma
T cell Leukemia/
Lymphoma
Acute Myeloid
Leukemia
Multiple
Myeloma
Hodgkin
Lymphoma
Product List
To support the research and development of hematologic malignancy cell therapies, we have developed a wide series of targets including covering different species and fluorescent labeling types. These products can be used for immune screening, CAR detection and PK study to accelerate your cell therapy research.
Product Features

Various species including human, mouse, monkey, rabbit, etc

High bioactivity verified by FACS/ELISA/SPR

Star Staining―Alexa Fluor 488/555/647, PE, APC, FITC-labels are available

Some products have been filed with FDA DMF to support your IND, NDA and BLA

Data
High purity
High purity

The purity of Human CD4, Fc Tag (MALS verified) (Cat. No. CD4-H5259) is more than 95% and the molecular weight of this protein is around 150-170 kDa verified by SEC-MALS.

High Bioactivity
> High bioactivity verified by ELISA for early antibody screening
High bioactivity verified by ELISA for early antibody screening

Immobilized Human / Cynomolgus / Rhesus macaque ROR1, Fc Tag (Cat. No. RO1-H5250) at 2 μg/mL (100 μL/well) can bind Anti-ROR1 Antibody, Human IgG1 with a linear range of 0.3-5 ng/mL (QC tested).

High bioactivity verified by ELISA for early antibody screening

Immobilized Human Siglec-2, Fc Tag (Cat. No. CD2-H5253) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human Siglec-2 Antibody, Human IgG1 with a linear range of 2-62.5 ng/mL (QC tested).

Star Staining products have higher binding activity than that of other competitors
Star Staining products have higher binding activity than that of other competitors
Star Staining products have higher binding activity than that of other competitors

Binding activity of FITC-Labeled Human BCMA and CD19 protein from two different vendors were evaluated by the FACS analysis. The result showed that ACRO's Star Staining FITC-Labeled Human BCMA (Cat. No. BCA-HF2H3) and CD19 (Cat. No. CD9-HF2H3) protein have a much higher binding activity than that of the other competitor.

No non-specific binding to non-transduced PBMCs
No non-specific binding to non-transduced PBMCs
No non-specific binding to non-transduced PBMCs

5e5 of PBMCs were stained with AF555-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HA2H7) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and AF555 signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

More Related Products

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message